Literature DB >> 8006765

Characterization and tissue distribution of liposomes containing lactose mono-fatty acid derivatives.

H Yamauchi1, H Kikuchi, M Sawada, M Tomikawa, S Hirota.   

Abstract

In this study we characterized liposomes containing the synthetic glycolipids, lactose mono-fatty acid esters (LFEs), whose structures were the most simple ones compared to the other synthetic glycolipids. Gel filtration chromatography was used to confirm that 78 per cent of lactose monostearic acid ester (LSE) or 85 per cent of lactose monoarachidic acid ester (LAE) existed in the liposomal fraction. The size distribution of liposomes containing LFEs was similar to that of the control liposomes which did not contain LFEs. Liposomes containing LFEs were aggregated by Ricinus communis agglutinin from caster bean (RCA120) while the control liposomes were not, with the agglutinability of the liposomes containing LAE being greater than that of those containing LSE. These findings therefore suggested that the LFEs were incorporated into the liposomal membrane with the galactose residues exposed to the outer aqueous phase. Next, the tissue distribution of liposomes containing LAE at 30 min after intravenous administration was compared to that of the control liposomes in rats. Hepatic uptake was 2-fold higher than that of the control liposomes. These results thus demonstrate that liposomes containing LFEs represent potential drug carriers to the liver.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8006765     DOI: 10.3109/02652049409040449

Source DB:  PubMed          Journal:  J Microencapsul        ISSN: 0265-2048            Impact factor:   3.142


  2 in total

1.  Hepatic immunopotentiation by galactose-entrapped liposomal IL-2 compound in the treatment of liver metastases.

Authors:  K Okuno; K Nakamura; A Tanaka; K Yachi; M Yasutomi
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

2.  Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies.

Authors:  A Adedoyin; J F Bernardo; C E Swenson; L E Bolsack; G Horwith; S DeWit; E Kelly; J Klasterksy; J P Sculier; D DeValeriola; E Anaissie; G Lopez-Berestein; A Llanos-Cuentas; A Boyle; R A Branch
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.